Xilio Therapeutics Business Summary

Xilio Therapeutics, Inc. (XLO) is a clinical-stage biotechnology company that generates revenue primarily through high-value strategic collaboration and license agreements, most notably with AbbVie and Gilead Sciences, supplemented by capital raises through public equity and warrant offerings. The company’s primary business segments are focused on the discovery and development of tumor-activated immuno-oncology (I-O) therapies, specifically engineered cytokines (IL-2 and IL-12), monoclonal antibodies (anti-CTLA-4), and masked T cell engagers. By leveraging its proprietary masking platform to localize anti-tumor activity within the tumor microenvironment, Xilio seeks to significantly widen the therapeutic index of potent I-O agents that are otherwise limited by systemic toxicity. The company competes directly with other precision-activation biotech firms such as Werewolf Therapeutics, Janux Therapeutics, and BioAtla, positioning itself as a specialized leader in the development of tumor-selective bispecifics and cytokines that remain inert until triggered by proteases in the tumor site. The company is led by President and CEO Dr. René Russo, a Pharm.D. with over 25 years of biopharmaceutical experience who previously played a pivotal role in the growth and $9.6 billion acquisition of Cubist Pharmaceuticals. The technical leadership is headed by Chief Scientific Officer Dr. Uli Bialucha, an oncology drug discovery veteran formerly of Novartis and Immunitas Therapeutics, alongside CFO and COO Chris Frankenfield, who joined from Blueprint Medicines. Xilio was founded in 2016 (originally as Akrevia Therapeutics) with foundational backing from premier life science investors Atlas Venture and F-Prime Capital. As of February 2026, the board is chaired by Sara Bonstein (CFO of Insmed) and includes notable industry figures such as Dr. Akintunde Bello (formerly of Bristol Myers Squibb) and Dr. James Shannon (former CMO of GlaxoSmithKline), reflecting a high-pedigree leadership team supported by strategic equity partners like Gilead Sciences and AbbVie.